April 30, 2025 01:41 PM EDT

Regeneron loses bid to fend off DOJ fight over Eylea Medicare payments

Alexis Kramer

Deputy Editor

Regeneron can’t dodge a lawsuit alleging it unlawfully inflated Medicare reimbursements for its eye drug Eylea and defrauded the US out of hundreds of millions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Regeneron loses bid to fend off DOJ fight over Eylea Medicare payments

Alexis Kramer

Deputy Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Exits continue at FDA, as more staff in drug office follow fired colleagues out the door

Updated: Novartis to buy Regulus Therapeutics for up to $1.7B

FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts

FDA approves J&J's rare disease drug that's expected to compete with argenx and UCB

The Endpoints Slack interview: Arc Institute's Patrick Hsu on investing, AI and new ways of research

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Re­gen­eron los­es bid to fend off DOJ fight over Eylea Medicare pay­ments

Deputy Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Regeneron loses bid to fend off DOJ fight over Eylea Medicare payments